JP7128121B2 - Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用 - Google Patents

Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用 Download PDF

Info

Publication number
JP7128121B2
JP7128121B2 JP2018567646A JP2018567646A JP7128121B2 JP 7128121 B2 JP7128121 B2 JP 7128121B2 JP 2018567646 A JP2018567646 A JP 2018567646A JP 2018567646 A JP2018567646 A JP 2018567646A JP 7128121 B2 JP7128121 B2 JP 7128121B2
Authority
JP
Japan
Prior art keywords
click
conjugate
pair
conjugates
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018567646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532012A (ja
JP2019532012A5 (https=
Inventor
ブライアン ディー ケリー，
ネーサン ダブリュ ポーラスキー，
Original Assignee
ヴェンタナ メディカル システムズ， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴェンタナ メディカル システムズ， インク． filed Critical ヴェンタナ メディカル システムズ， インク．
Publication of JP2019532012A publication Critical patent/JP2019532012A/ja
Publication of JP2019532012A5 publication Critical patent/JP2019532012A5/ja
Priority to JP2022084324A priority Critical patent/JP2022126650A/ja
Application granted granted Critical
Publication of JP7128121B2 publication Critical patent/JP7128121B2/ja
Priority to JP2024114392A priority patent/JP7737517B2/ja
Priority to JP2025142894A priority patent/JP2026000932A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/08—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
    • C07C247/10—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/08—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/650947—Six-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
JP2018567646A 2016-06-28 2017-06-27 Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用 Active JP7128121B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022084324A JP2022126650A (ja) 2016-06-28 2022-05-24 Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
JP2024114392A JP7737517B2 (ja) 2016-06-28 2024-07-18 Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
JP2025142894A JP2026000932A (ja) 2016-06-28 2025-08-29 Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662355390P 2016-06-28 2016-06-28
US62/355,390 2016-06-28
PCT/EP2017/065796 WO2018002016A1 (en) 2016-06-28 2017-06-27 Application of click chemistry for signal amplification in ihc and ish assays

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022084324A Division JP2022126650A (ja) 2016-06-28 2022-05-24 Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用

Publications (3)

Publication Number Publication Date
JP2019532012A JP2019532012A (ja) 2019-11-07
JP2019532012A5 JP2019532012A5 (https=) 2020-07-30
JP7128121B2 true JP7128121B2 (ja) 2022-08-30

Family

ID=59350876

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018567646A Active JP7128121B2 (ja) 2016-06-28 2017-06-27 Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
JP2022084324A Withdrawn JP2022126650A (ja) 2016-06-28 2022-05-24 Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
JP2024114392A Active JP7737517B2 (ja) 2016-06-28 2024-07-18 Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
JP2025142894A Pending JP2026000932A (ja) 2016-06-28 2025-08-29 Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022084324A Withdrawn JP2022126650A (ja) 2016-06-28 2022-05-24 Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
JP2024114392A Active JP7737517B2 (ja) 2016-06-28 2024-07-18 Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
JP2025142894A Pending JP2026000932A (ja) 2016-06-28 2025-08-29 Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用

Country Status (5)

Country Link
US (5) US11249085B2 (https=)
EP (2) EP4631529A3 (https=)
JP (4) JP7128121B2 (https=)
CN (2) CN121021395A (https=)
WO (1) WO2018002016A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024161373A (ja) * 2016-06-28 2024-11-19 ヴェンタナ メディカル システムズ， インク． Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2940439C (en) * 2014-02-24 2024-03-19 Ventana Medical Systems, Inc. Quinone methide analog signal amplification
WO2018002015A1 (en) * 2016-06-28 2018-01-04 Ventana Medical Systems, Inc. New colors for chromogenic ihc and ish staining with multi-dye quinone methide and tyramide conjugates
US11492610B2 (en) 2018-03-08 2022-11-08 California Institute Of Technology Sample multiplexing for single-cell RNA sequencing
JP7455816B2 (ja) 2018-09-20 2024-03-26 ヴェンタナ メディカル システムズ， インク． クマリン系架橋試薬
ES3011267T3 (en) * 2019-06-07 2025-04-07 Univ Princeton Proximity-based labeling systems and applications thereof
CN112305227A (zh) * 2019-07-31 2021-02-02 深圳市帝迈生物技术有限公司 自交联蛋白、配体组合物、制备方法、试剂盒及系统
EP4073064A4 (en) * 2019-12-11 2024-01-24 The General Hospital Corporation METHOD FOR IMAGING CELLS
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
CN112113820A (zh) * 2020-05-28 2020-12-22 王剑 一种细胞病理学样本的染色制片方法
CA3189327A1 (en) 2020-08-19 2022-02-24 Vijaya Raghavan PATTABIRAMAN Modified il-18 polypeptides and uses thereof
WO2022043491A2 (en) * 2020-08-28 2022-03-03 Ventana Medical Systems, Inc. Conjugates including a detectable moiety
WO2022066512A1 (en) 2020-09-22 2022-03-31 Ventana Medical Systems, Inc. Prediction of response to epidermal growth factor receptor-directed therapies using epiregulin and amphiregulin
WO2022092301A1 (ja) * 2020-10-30 2022-05-05 株式会社ナード研究所 シクロオクチン誘導体またはその塩、これを用いた標的分子の濃縮方法および検出方法、ならびに濃縮または検出用キット
WO2022152777A1 (en) 2021-01-15 2022-07-21 F. Hoffmann-La Roche Ag Storage stable caged haptens
WO2022156920A1 (en) 2021-01-25 2022-07-28 Ventana Medical Systems, Inc. Stained biological specimens including one or more biomarkers labeled with one or more detectable moieties
JP2024516380A (ja) * 2021-04-18 2024-04-15 ヴェンタナ メディカル システムズ， インク． 形態学的マーカー染色
EP4337092A1 (en) 2021-05-13 2024-03-20 Ventana Medical Systems, Inc. Real-time prediction of tissue fixation time
AU2022306974A1 (en) 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
WO2023281480A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Conjugates of checkpoint inhibitors with il-2, and uses thereof
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
EP4366781A1 (en) 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Checkpoint inhibitors conjugated to il-2, and uses thereof
CN113567677B (zh) * 2021-07-23 2024-04-12 湖北百奥斯生物科技有限公司 一种免疫荧光信号放大技术标记方法
CN113552362B (zh) * 2021-07-23 2024-08-09 湖北百奥斯生物科技有限公司 一种新型信号放大的免疫荧光试剂盒
CN113564229B (zh) * 2021-07-28 2022-04-01 中国人民解放军陆军军医大学 基于点击化学连接和发夹堆叠组装检测microRNA的试剂和方法
WO2023058624A1 (ja) * 2021-10-08 2023-04-13 コニカミノルタ株式会社 染色方法、評価方法および標本
CA3244053A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag MODIFIED IL-18 POLYPEPTIDES
AU2023226005A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
WO2024002924A2 (en) * 2022-06-28 2024-01-04 F. Hoffmann-La Roche Ag Fluorescent dyes with large stokes shift
WO2024064338A1 (en) 2022-09-22 2024-03-28 Agilent Technologies, Inc. Anti-human icos antibodies for use in immunohistochemistry (ihc) protocols and for diagnosing cancer
WO2024137817A1 (en) 2022-12-23 2024-06-27 Ventana Medical Systems, Inc. Materials and methods for evaluation of antigen presentation machinery components and uses thereof
US20240424127A1 (en) 2023-01-11 2024-12-26 Bright Peak Therapeutics Ag Il-7 polypeptides, immunocytokines comprising same, and uses thereof
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024215528A1 (en) 2023-04-13 2024-10-17 Ventana Medical Systems, Inc. Proliferation assay for fixed solid tumors
WO2024263272A2 (en) * 2023-06-20 2024-12-26 Arizona Board Of Regents On Behalf Of Arizona State University Methods and systems for sensitive and multiplexed analysis of biological samples using cleavable fluorphores and 'click' chemistry
WO2025014787A1 (en) 2023-07-07 2025-01-16 Ventana Medical Systems, Inc. Brightfield triplex immunohistochemistry assay for evaluating the colocalization of the er, pr, and ki-67 biomarkers in cells
WO2025041102A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
US20250186594A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides modified with polymers
US20250213705A1 (en) 2023-08-23 2025-07-03 Bright Peak Therapeutics Ag Psma targeting ligands and methods of use
WO2025137443A1 (en) 2023-12-22 2025-06-26 Rayzebio, Inc. Radiopharmaceutical compositions targeting somatostatin receptors and uses thereof
US20250222146A1 (en) 2023-12-22 2025-07-10 Rayzebio, Inc. Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof
WO2025193604A1 (en) 2024-03-11 2025-09-18 Ventana Medical Systems, Inc. Non-enzymatic dissociation of ffpe tissue and generation of single cells with intact cell surface markers
WO2026069134A1 (en) 2024-09-26 2026-04-02 Bright Peak Therapeutics Ag Human therapy with il-18 immunocytokines
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010122071A (ja) 2008-11-19 2010-06-03 Okayama Univ 物質を固定化した物質固定化担体および物質固定化担体を作製する方法
US20120029186A1 (en) 2010-07-29 2012-02-02 Popik Vladimir V Aza-dibenzocyclooctynes and methods of making and using same
US20120208722A1 (en) 2010-10-19 2012-08-16 Richard Dluhy Surface enhanced raman spectroscopy platforms and methods
WO2012152807A1 (en) 2011-05-09 2012-11-15 Universiteit Antwerpen Activity-based probes for the urokinase plasminogen activator
US20130281656A1 (en) 2012-04-23 2013-10-24 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Methods for labeling a substrate having a plurality of thiol groups attached thereto
WO2015124703A1 (en) 2014-02-24 2015-08-27 Ventana Medical Systems, Inc. Quinone methide analog signal amplification
JP2015534996A (ja) 2012-10-23 2015-12-07 シンアフィックス ビー．ブイ． 修飾抗体、抗体コンジュゲート及びそれらを調製する方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196306A (en) 1989-03-29 1993-03-23 E. I. Du Pont De Nemours And Company Method for the detection or quantitation of an analyte using an analyte dependent enzyme activation system
US5595707A (en) 1990-03-02 1997-01-21 Ventana Medical Systems, Inc. Automated biological reaction apparatus
US20030211630A1 (en) 1998-02-27 2003-11-13 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
US6582962B1 (en) 1998-02-27 2003-06-24 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
JP3847559B2 (ja) 1998-02-27 2006-11-22 ベンタナ・メデイカル・システムズ・インコーポレーテツド 独立スライド加熱器を有する自動化分子病理学装置
EP1084269B1 (en) * 1998-06-04 2007-04-25 PerkinElmer LAS, Inc. Novel peroxidase substrates and their use in catalyzed reporter deposition
CA2342767C (en) 1998-09-03 2009-11-03 Trellis Bioinformatics, Inc. Multihued labels
EP1415156B1 (en) 2001-07-10 2009-09-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of multiple proteins in single cells
US6855503B2 (en) * 2002-12-20 2005-02-15 Amersham Biosciences Corp Heterocyclic FRETdye cassettes for labeling biological molecules and their use in DNA sequencing
JP2004210733A (ja) * 2003-01-07 2004-07-29 Kyowa Hakko Kogyo Co Ltd アリールスルファマート誘導体
US20070009980A1 (en) 2004-06-01 2007-01-11 Applera Corporation Continuous fluorogenic analyte assays with dendritic amplification of signal
CA2609702C (en) 2005-04-28 2013-05-28 Ventana Medical Systems, Inc. Antibody conjugates via heterobifunctional peg linkers
US20070117153A1 (en) 2005-11-23 2007-05-24 Christopher Bieniarz Molecular conjugate
US8158444B2 (en) 2006-10-06 2012-04-17 Sirigen, Inc. Fluorescent methods and materials for directed biomarker signal amplification
DK2444807T3 (da) 2006-11-01 2014-08-11 Ventana Med Syst Inc Mono- og dinitropyrazolhaptenkonjugater
EP2167963B1 (en) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
EP2222341B1 (en) 2007-11-21 2015-02-25 University Of Georgia Research Foundation, Inc. Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds
EP2334827B1 (en) 2008-08-22 2015-03-11 Ventana Medical Systems, Inc. Method for chromogenic detection of two or more target molecules in a single sample
US8900549B2 (en) 2008-10-31 2014-12-02 The General Hospital Corporation Compositions and methods for delivering a substance to a biological target
WO2010111674A2 (en) 2009-03-27 2010-09-30 Life Technologies Corporation Methods and apparatus for single molecule sequencing using energy transfer detection
CA2842661C (en) 2009-10-19 2016-02-23 Ventana Medical Systems, Inc. Imaging system and techniques
SG190892A1 (en) 2010-12-30 2013-07-31 Ventana Med Syst Inc Enhanced deposition of chromogens utilizing pyrimidine analogs
WO2012112563A2 (en) * 2011-02-16 2012-08-23 Magic Technologies, Inc. Methods and compositions for the target-localized anchoring of detectable label
US9448173B2 (en) * 2011-03-08 2016-09-20 The Board Of Trustees Of The University Of Illinois Dye-conjugated dendrimers
US9624524B2 (en) * 2011-06-15 2017-04-18 Massachusetts Institute Of Technology In vivo proteomic mapping
CN105204152B (zh) 2011-09-09 2018-10-26 文塔纳医疗系统公司 成像系统、盒和使用其的方法
ES2678211T3 (es) * 2012-03-27 2018-08-09 Ventana Medical Systems, Inc. Conjugados de señalización y procedimientos de uso
US10610608B2 (en) * 2013-08-01 2020-04-07 Rochester Institute Of Technology Modular imaging agents containing amino acids and peptides
US11168085B2 (en) 2014-01-24 2021-11-09 Synaffix B.V. Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne
US20170119892A1 (en) * 2014-04-04 2017-05-04 President And Fellows Of Harvard College Refillable drug delivery devices and methods of use thereof
US10758895B2 (en) 2014-09-30 2020-09-01 University of Pittsburgh—of the Commonwealth System of Higher Education Cu(I)-catalyzed azide-alkyne cycloadditions (CuAAC) ligands and methods for carrying out Cu(I)-catalyzed azide-alkyne cycloaddition reactions
US10335495B2 (en) 2014-12-04 2019-07-02 Celgene Corporation Biomolecule conjugates
WO2018002015A1 (en) * 2016-06-28 2018-01-04 Ventana Medical Systems, Inc. New colors for chromogenic ihc and ish staining with multi-dye quinone methide and tyramide conjugates
JP7128121B2 (ja) 2016-06-28 2022-08-30 ヴェンタナ メディカル システムズ， インク． Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010122071A (ja) 2008-11-19 2010-06-03 Okayama Univ 物質を固定化した物質固定化担体および物質固定化担体を作製する方法
US20120029186A1 (en) 2010-07-29 2012-02-02 Popik Vladimir V Aza-dibenzocyclooctynes and methods of making and using same
US20120208722A1 (en) 2010-10-19 2012-08-16 Richard Dluhy Surface enhanced raman spectroscopy platforms and methods
WO2012152807A1 (en) 2011-05-09 2012-11-15 Universiteit Antwerpen Activity-based probes for the urokinase plasminogen activator
US20130281656A1 (en) 2012-04-23 2013-10-24 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Methods for labeling a substrate having a plurality of thiol groups attached thereto
JP2015534996A (ja) 2012-10-23 2015-12-07 シンアフィックス ビー．ブイ． 修飾抗体、抗体コンジュゲート及びそれらを調製する方法
WO2015124703A1 (en) 2014-02-24 2015-08-27 Ventana Medical Systems, Inc. Quinone methide analog signal amplification

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024161373A (ja) * 2016-06-28 2024-11-19 ヴェンタナ メディカル システムズ， インク． Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
JP7737517B2 (ja) 2016-06-28 2025-09-10 ヴェンタナ メディカル システムズ， インク． Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用

Also Published As

Publication number Publication date
JP2026000932A (ja) 2026-01-06
WO2018002016A1 (en) 2018-01-04
US20250271441A1 (en) 2025-08-28
JP2024161373A (ja) 2024-11-19
EP4631529A3 (en) 2026-03-11
CN121021395A (zh) 2025-11-28
US20220146520A1 (en) 2022-05-12
JP7737517B2 (ja) 2025-09-10
JP2022126650A (ja) 2022-08-30
US12372531B2 (en) 2025-07-29
JP2019532012A (ja) 2019-11-07
US20190204330A1 (en) 2019-07-04
US20220155312A1 (en) 2022-05-19
US20210123922A1 (en) 2021-04-29
CN109641922B (zh) 2025-08-29
CN109641922A (zh) 2019-04-16
EP3475291A1 (en) 2019-05-01
US11249085B2 (en) 2022-02-15
US11860167B2 (en) 2024-01-02
EP3475291B1 (en) 2025-10-01
EP4631529A2 (en) 2025-10-15
US12517132B2 (en) 2026-01-06

Similar Documents

Publication Publication Date Title
JP7737517B2 (ja) Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
JP7394895B2 (ja) マルチ色素キノンメチド及びチラミドコンジュゲートによる発色性ｉｈｃ及びｉｓｈ染色のための新規の色
US12173031B2 (en) Peptide nucleic acid conjugates
CN109791144B (zh) 使用经掩蔽的半抗原在福尔马林固定的石蜡包埋的组织中的蛋白邻近测定法
JP2024504944A (ja) 保存安定なケージドハプテン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200612

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220524

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220524

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220602

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220726

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220818

R150 Certificate of patent or registration of utility model

Ref document number: 7128121

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250